Oxycodone and Palmitoylethanolamine Combination for Opioid Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid therapies face challenges in minimizing side effects such as irritation, confusion, and uncontrolled movement associated with oxycodone use, while also dealing with opioid dependence and addiction, and there is a need for compositions that enhance opioid potency and safety.
Innovation Solution
Pharmaceutical compositions combining oxycodone with N-acylethanolamines, specifically palmitoylethanolamine (PEA), in specific molar ratios for systemic administration, which potentiates the therapeutic effect of opioids and reduces side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oxycodone is administered to achieve analgesic effect, then pain relief is improved, but side effects such as irritation, confusion, and uncontrolled movement increase
Solution Approach 1:
The patent introduces N-acylethanolamines as intermediary substances that mediate between oxycodone and the body's neural system. These intermediaries modulate opioid receptor activation, providing analgesic effects while reducing harmful side effects through balanced receptor interaction.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining oxycodone with N-acylethanolamines in specific ratios. This composite approach leverages the synergistic effects of both substances, where N-acylethanolamines enhance opioid potency while simultaneously reducing side effects through their own pharmacological properties.
2Reliability
If oxycodone dosage is increased to enhance therapeutic potency, then pain relief is improved, but risk of addiction and dependence increases
Solution Approach 1:
The patent changes the compositional parameters of the pharmaceutical formulation by incorporating N-acylethanolamines alongside oxycodone. This parameter modification allows for reduced oxycodone dosage while maintaining therapeutic potency, thereby lowering addiction risk through decreased exposure to the addictive substance.
Solution Approach 2:
N-acylethanolamines serve as intermediary agents that enhance the therapeutic effects of lower oxycodone doses. By mediating the pharmacological response, they allow effective pain management at reduced opioid levels, minimizing the development of dependence and addiction.
3Reliability
If oxycodone is used to treat pain, then analgesic effect is achieved, but required dosage is high leading to increased side effects
Solution Approach 1:
The patent merges oxycodone with N-acylethanolamines in a combined pharmaceutical formulation. This merging creates a synergistic effect where the total analgesic potency is enhanced, allowing for reduced oxycodone dosage while maintaining or improving pain relief effectiveness.
Solution Approach 2:
The composite formulation of oxycodone and N-acylethanolamines creates a more potent therapeutic agent per unit dose. This composite material approach increases the effective concentration of analgesic activity, reducing the quantity of oxycodone needed to achieve the desired therapeutic effect.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The present invention provides pharmaceutical compositions comprising opioids and N-acylethanolamines, and methods for their use in preventing and treating a variety of opioid- responsive conditions and opioid-related side-effects.